Company intelligence / Profile preview

CHO Plus

South San Francisco, California, United Statescho-plus.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

The company has demonstrated a 10-fold protein productivity increase for CHO Plus engineered cells compared to parent cells in a model system, and in other documentation mentions up to 4.5-fold more productivity than parent cells[1][4]

Modalities: Therapeutic proteinsViruses
Industry: Non-Drug Biotech

Partnerships

Janssen Biotechnology (Johnson & Johnson)[2]

Beyond the preview

Go deeper on CHO Plus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHO Plus.

Explore the full profile